CCL = Chemokine (C-C motif) ligand; G-CSF = granulocyte-colony stimulating factor; GM-CSF = Granulocyte-macrophage CSF; FGF = fibroblast growth factor; CRP = C-reactive protein; FGF = fibroblast growth factor; GLP = glucagon-like peptide; GRO = growth-related protein; IFN = interferon; IL = interleukin; MIP = macrophage inflammatory factor; SAP = Serum Amyloid P; sCD40L = soluble CD40 ligand; SCGF = stem cell growth factor; TRAIL = TNF-related apoptosis-inducing ligand; VEGF = vascular endothelial growth factor. False discovery rate (FDR)-adjusted p-values are also shown. Cell populations with 'X' identifications are percentages by FACS. Figure S1 . Random forests analysis of CRP-high vs. CRP-low participant subgroups. Random forests analysis was used to identify variables of greatest importance (top of list) in discriminating between CRP high and low study participants. As shown, IL-6 was found to be the top discriminating biomarker.
Mean Decrease Accuracy Mean Decrease Gini 4 6 6 10 12 0 0.1 0.2 0.3 Figure S2 . Effect of rosuvastatin on immune measures. Measures were plotted in study subjects at the indicated trial timepoints (baseline [day 0], rosuvastatin treatment [days 14, 28], and 14 days after rosuvastatin discontinuation [day 42]). Subjects with low vs. high CRP at baseline are plotted separately. Boxes depict the interquartile range (IQR) around the median. The upper whisker extends from the hinge to the largest value no further than 1.5 * IQR from the hinge; the lower whisker extends from the hinge to the smallest value at most 1.5 * IQR of the hinge. Outlying points are plotted individually. Nominal P values for rosuvastatin treatment and/or discontinuation, which were determined for the overall study group by linear regression, are shown in the figure panels (also listed in Tables II and III) . 
